Los puntos clave no están disponibles para este artículo en este momento.
This Viewpoint discusses the need to achieve consensus around management strategies for patients with hyperlipidemia when proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors enter the marketplace.
Shrank et al. (Mon,) studied this question.